Erratum: Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer (Clinical Cancer Research (2019) 12(5199–5206)Doi:10.1158/1078-0432.CCR-06-0429)

Samuel K. Kulp, Chang Shi Chen, Da Sheng Wang, Ching Yu Chen, Ching Shih Chen

Research output: Contribution to journalComment/debatepeer-review

Abstract

This article (1) has been retracted at the request of the editors. Following an institutional review by Ohio State University, the primary affiliation for several of the authors, it was determined that data in Fig. 4A was falsified. As a result of these findings, the institution recommended retraction and, upon internal review, the editors agreed with this recommendation. A copy of this Retraction Notice was sent to the last known e-mail addresses for all authors. Two authors (Samuel K. Kulp and Ching-Shih Chen) agreed to the retraction, and three authors (Chang-Shi Chen, Da-Sheng Wang, and Ching-Yu Chen) did not respond.

Original languageEnglish
Number of pages1
JournalClinical Cancer Research
Volume25
Issue number9
DOIs
Publication statusPublished - 2006 Sep 1

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Erratum: Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer (Clinical Cancer Research (2019) 12(5199–5206)Doi:10.1158/1078-0432.CCR-06-0429)'. Together they form a unique fingerprint.

Cite this